Core Viewpoint - Mueller Water Products (MWA) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [1][2]. - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Business Outlook for Mueller Water Products - The recent increase in earnings estimates for Mueller Water Products indicates an improvement in the company's underlying business, which is expected to drive the stock price higher [5][10]. - The Zacks Consensus Estimate for Mueller Water Products is projected at $1.45 per share for the fiscal year ending September 2026, with a 3.3% increase in estimates over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Core Viewpoint - The analysis compares Banco Santander (SAN) and Nordea Bank AB (NRDBY) to determine which stock offers better value for investors at the current time [1] Valuation Metrics - Both Banco Santander and Nordea Bank AB have a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks [3] - Banco Santander has a forward P/E ratio of 10.24, while Nordea Bank AB has a forward P/E of 11.00, suggesting that SAN may be undervalued compared to NRDBY [5] - The PEG ratio for Banco Santander is 0.69, indicating a favorable valuation relative to its expected earnings growth, whereas Nordea Bank AB has a PEG ratio of 3.26, suggesting it may be overvalued [5] - Banco Santander's P/B ratio is 1.33, compared to Nordea Bank AB's P/B of 1.74, further supporting the notion that SAN is a better value option [6] - Based on these valuation metrics, Banco Santander is rated with a Value grade of A, while Nordea Bank AB has a Value grade of F, highlighting the significant difference in perceived value [6][7]

Core Viewpoint - S&P Global reported mixed fourth-quarter 2025 results, with earnings missing estimates while revenues exceeded expectations, leading to a mixed outlook for the company's stock performance going forward [3][4][8]. Financial Performance - Adjusted earnings per share (EPS) for Q4 2025 were $4.30, slightly below the Zacks Consensus Estimate, but represented a year-over-year increase of 14.1% [3]. - Revenues for the quarter reached $3.92 billion, surpassing consensus estimates and showing a 9% year-over-year growth [3]. - Adjusted operating profit was $1.90 billion, reflecting a 12% increase year-over-year, with an operating profit margin of 47.3%, up 60 basis points from the previous year [5]. Segment Performance - Marketing Intelligence revenues were $1.26 billion, a 7% increase from the previous year [4]. - Ratings revenues grew 12% to $1.19 billion [4]. - Revenues from Energy Organic were $576 million, up 6% year-over-year [4]. - Mobility and Indices segments saw increases of 8% and 14%, reaching $444 million and $498 million, respectively [4]. Balance Sheet and Cash Flow - The company ended Q4 2025 with cash and cash equivalents of $1.75 billion, up from $1.67 billion in Q4 2024 [6]. - Long-term debt increased to $12.37 billion from $11.39 billion year-over-year [6]. - Cash generated from operating activities was $1.75 billion, with capital expenditures of $46 million and free cash flow of $1.6 billion [6]. Shareholder Returns - In 2025, S&P Global returned $6.2 billion to shareholders, which included $1.2 billion in dividends and $5.0 billion in share repurchases [7]. 2026 Outlook - For 2026, S&P Global expects adjusted EPS to be between $19.40 and $19.65, with revenue growth guidance raised to 6-8% [8]. - Capital expenditure guidance is set at $215-$225 million, and the expected full-year tax rate is between 22-23% [8]. Market Position and Comparisons - S&P Global's stock has seen a downward trend in estimates since the earnings release, leading to a Zacks Rank of 4 (Sell) [9][12]. - In comparison, Nasdaq, a peer in the Securities and Exchanges industry, reported revenues of $1.39 billion for the last quarter, a year-over-year increase of 13.4%, and has a Zacks Rank of 2 (Buy) [13][14].

Core Viewpoint - The market anticipates a year-over-year decline in FedEx's earnings despite an increase in revenues when the company reports its quarterly results for February 2026 [1] Earnings Expectations - FedEx is expected to report quarterly earnings of $4.12 per share, reflecting a year-over-year decrease of 8.7% [3] - Revenues are projected to reach $23.58 billion, which is a 6.4% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.47% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for FedEx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.84% [12] Earnings Surprise History - In the last reported quarter, FedEx exceeded the expected earnings of $4.07 per share by delivering $4.82, resulting in a surprise of +18.43% [13] - Over the past four quarters, FedEx has beaten consensus EPS estimates three times [14] Predictive Indicators - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Monte Rosa Therapeutics due to lower revenues, with a focus on how actual results will compare to estimates [1] Earnings Expectations - Monte Rosa Therapeutics is expected to report a quarterly loss of $0.47 per share, reflecting a year-over-year change of -304.4% [3] - Revenues are projected to be $10.26 million, down 83.1% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 6.52% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Monte Rosa is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.13% [11] Earnings Surprise Potential - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9] - Monte Rosa has a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Monte Rosa was expected to post a loss of $0.39 per share but actually reported a loss of -$0.33, resulting in a surprise of +15.38% [12] - The company has beaten consensus EPS estimates in the last four quarters [13] Industry Context - Kyntra Bio, another company in the biomedical and genetics industry, is expected to report a loss of $3.89 per share, indicating a year-over-year change of -94.5% [17] - Kyntra Bio's revenues are expected to be $1.6 million, down 49% from the previous year, with an Earnings ESP of +24.07% [18][19]

Core Viewpoint - Arcos Dorados (ARCO) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for March 19, and if the reported figures exceed expectations, the stock may experience an upward movement; conversely, missing expectations could lead to a decline [2]. - The consensus estimate for quarterly earnings is projected at $0.20 per share, reflecting a year-over-year decrease of 28.6%, while revenues are expected to reach $1.26 billion, marking a 10.2% increase from the previous year [3]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 23.08%, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Arcos Dorados aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with positive readings being more reliable [9][10]. - Arcos Dorados currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Arcos Dorados was expected to earn $0.10 per share but exceeded this with actual earnings of $0.12, resulting in a positive surprise of 20% [13]. - Over the last four quarters, the company has surpassed consensus EPS estimates three times [14]. Conclusion - While Arcos Dorados does not appear to be a strong candidate for an earnings beat, investors should consider other factors when deciding on their investment strategy ahead of the earnings release [17].

Core Viewpoint - GT Biopharma, Inc. (GTBP) has experienced a decline of 6.6% in its stock price over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with reduced selling pressure and a potential shift in control from bears to bulls [2][5]. - This pattern is characterized by a small candle body with a long lower wick, signifying that despite a new low being reached, buying interest has emerged to push the stock price up towards its opening price [4][5]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for GTBP, with a 54.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating strong agreement among analysts that the company will report better earnings than previously predicted [7][8]. - GTBP holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically correlates with outperformance in the market [9][10].

Group 1 - Bentley Systems, Incorporated (BSY) shares have increased by 14% over the past four weeks, closing at $38.66, with a mean price target of $48.54 indicating a potential upside of 25.6% [1] - The average price target consists of 13 estimates ranging from a low of $42.00 to a high of $61.00, with a standard deviation of $5.49, suggesting a consensus among analysts [2] - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] Group 2 - Over the last 30 days, four earnings estimates for BSY have been revised upward, leading to a 6.7% increase in the Zacks Consensus Estimate [12] - BSY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be entirely reliable, the direction it suggests appears to be a good guide for potential price movement [14]

Core Viewpoint - InnovAge Holding Corp. (INNV) has experienced a bearish trend, losing 19% in the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick, suggesting that the stock may be nearing a bottom and that selling pressure could be exhausting [4][5]. - This pattern typically forms during a downtrend when bears have control, but a subsequent buying interest can signal a potential reversal [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for INNV, which is considered a bullish indicator, as it often leads to price appreciation [7]. - The consensus EPS estimate for the current year has increased by 1.3% over the last 30 days, indicating that analysts expect better earnings than previously predicted [8]. - INNV holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Health Catalyst (HCAT) has experienced a bearish trend recently, losing 6.5% over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2] Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][5] - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling a possible reversal if it appears at the bottom of the trend [4][5] Fundamental Analysis - There has been a positive trend in earnings estimate revisions for HCAT, which is a bullish indicator and suggests potential price appreciation in the near term [7] - Over the last 30 days, the consensus EPS estimate for HCAT has increased by 100%, indicating that analysts expect better earnings than previously predicted [8] - HCAT currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]